

Orthocell appoints specialist US-based nerve surgeons to medical advisory board

- Orthocell appoints internationally recognised orthopaedic surgeons, Professor Christopher Dy and Professor David Brogan, specialising in nerve transfer and peripheral nerve repair to its Medical Scientific Advisory Board
- Professors Dy and Brogan are based at Washington University and Barnes-Jewish Orthopedic Center, one of the US's leading academic research institutions and hospitals, and have been appointed to assist with clinical development and US market access for Orthocell's nerve repair medical device
- Both surgeons bring a wealth of clinical and research expertise, including significant experience advancing pre-clinical and clinical research programs
- With these additions to the specialist advisory team, Orthocell is ideally positioned to drive its market leading nerve repair medical device into the US market

Perth, Australia; 29 March 2023: Regenerative medicine company Orthocell Limited (ASX:OCC, "Orthocell" or the "Company") is pleased to announce the appointment of Dr Christopher Dy and Dr David Brogan to its Medical and Scientific Advisory board.

Orthocell Managing Director, Paul Anderson, said: "We are delighted to welcome Professors Dy and Brogan to the Orthocell MSAB. Both are globally recognized nerve reconstructive surgeons, with a passion for translating medical research and delivering the highest quality patient care. We are also delighted to be collaborating with Washington University, one of the leading centres for nerve reconstructive surgery in the USA. These appointments, along with the recent appointment of Dr Ravi Thadhani to the Orthocell board of directors, adds significant depth to our US team and ability to execute our commercialization plans.

Professors Christopher Dy and David Brogan are orthopaedic surgeons, specializing in the treatment of nerve injuries, while also leading a comprehensive research program that is directly relevant to patients, clinicians, scientists, and policy-makers. Their translational research is focused on the epidemiologic, economic, and clinical analysis of peripheral and brachial plexus nerve injuries.

Professors Dy and Brogan are based at Washington University, which has a respected and highly-ranked research ecosystem. Washington University has affiliations with 26 Nobel laureates in economics, physiology and medicine, chemistry, and physics, 11 of whom conducted the major part of their pioneering research at the university.

About Dr Christopher Dy

Professor Dy is an internationally recognized orthopaedic surgeon specializing in the treatment of brachial plexus and peripheral nerve injuries (upper and lower limbs), using nerve transfers, nerve reconstructions, nerve decompressions and carpal and cubital tunnel release. Dr Dy has published

numerous peer reviewed research and clinical papers in top tier journals, in the areas of brachial plexus and peripheral nerve injuries. Dr Dy has received multiple awards for his contributions to research and advancing treatment of nerve injuries. To learn more [click here](#).

About Professor David Brogan

Professor David Brogan is a multi-credentialled surgeon and health professional who specializes in treating conditions of the hand and upper extremity, including fractures, arthritis of the wrist, elbow and hand. He has a patient centric approach with special expertise in treating nerve injuries, including peripheral nerve injuries, compression neuropathies (carpal tunnel, peroneal nerve injury, brachial plexus injury), complex microsurgical reconstruction, and upper extremity trauma. Dr Brogan has received multiple awards for his contributions to research and advancing treatment of nerve injuries. To learn more [click here](#).

The appointment of Professors Dy and Brogan to the MSAB will assist Orthocell in the design and implementation of the US-focused development strategy (pre-clinical and clinical) for the nerve repair regulatory and market access program. Their association with Orthocell will enable the Company to foster further collaborations, assist with interactions with the US FDA and to present data and product experiences in clinical and other settings in the US nerve repair market.

Release authorised by:

Paul Anderson
Managing Director, Orthocell Ltd

For more information, please contact:

General & Investor enquiries

Paul Anderson
Orthocell Limited
Managing Director

P: +61 8 9360 2888

E: paulanderson@orthocell.com.au

Media enquiries

Haley Chartres
H[^]CK Director

P: +61 423 139 163

E: haley@hck.digital

Orthocell is a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Orthocell's portfolio of products include CelGro™, a collagen medical device which facilitates tissue reconstruction and healing in a variety of dental and orthopaedic reconstructive applications. Striate+™ was the first product approved for dental GBR applications, is cleared for use in US FDA (510k), Australia (ARTG) and Europe (CE Mark) and is distributed globally by BioHorizons Implant Systems Inc. Remplir™, for peripheral nerve reconstruction, recently received approval and reimbursement in Australia and is distributed exclusively by Device Technologies in the Australian market SmrtGraft™, for tendon repair, is available in Australia under Special Access Scheme or participation in a clinical trial. The Company's other major products are autologous cell therapies which aim to regenerate damaged tendon and cartilage tissue. Orthocell is accelerating the development of its tendon cell therapy in the US with technology transfer, manufacturing scale up and FDA engagement in advance of a randomised controlled study under FDA supervision.

For more information on Orthocell, please visit www.orthocell.com or follow us on Twitter [@OrthocellLtd](https://twitter.com/OrthocellLtd) and LinkedIn www.linkedin.com/company/orthocell-ltd

Forward Looking Statement

Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.